IRCT20220209053979N4尚未招募未知
A cross over bioequivalence study of Niloitinib 150mg capsule of Sobhan Oncology compared to Tasigna 150 mg capsule manufactured by Novartis in 24 healthy volunteers under fasting condition
Sobhan Oncology0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Healthy adult male (18 - 55 yrs) and sterile or post menopausal female subjects
- •Body mass index (BMI) >18 but <30.
- •Laboratory parameter values must fall within the normal range
排除标准
- •History of clinically significant Electrocardiogram abnormalities, or a history/family history of long QT-interval syndrome.
研究者
相似试验
已完成
不适用
A bioequivalence study of Sunitinib 50 mg capsules of Sobhanoncology compared to Sutent 50 mg Capsule manufactured by Pfizer in 24 healthy volunteers under fasting conditioBioequivalence study.IRCT20220209053979N3Sobhan Oncology24
招募中
不适用
Bioequivalence study of Nilotinib 200mg capsuleThis study is performed on healthy volunteers..IRCT20200623047902N21Zistdaru danesh Co.24
尚未招募
不适用
Bioequivalence study of Nilotinib 200mg capsuleThis study is performed on healthy volunteers..IRCT20200623047902N17Rooyan darou company24
尚未招募
不适用
Study of absorption and elimination rate of Ibrutinib 140 -mg Capsules in comparison with Ibrutinib brand capsules (Imbruvica®)IRCT20200407046981N43Kimia pharmaceutical Co24
已完成
不适用
Comparative in vivo evaluation of 2 ?Linagliptin 5 mg Tablet formulations.Diabetes mellitus.Diabetes mellitus due to underlying conditionIRCT20180620040164N38Actover Pharmaceutical Co.24